Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials
| Autor: | Shenhong Wu, Anu Radha Neerukonda, Shiney Koshy |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Everolimus business.industry Anemia Cancer macromolecular substances medicine.disease Discovery and development of mTOR inhibitors Temsirolimus law.invention Randomized controlled trial law Meta-analysis Internal medicine medicine business PI3K/AKT/mTOR pathway medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 32:e13534-e13534 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2014.32.15_suppl.e13534 |
| Popis: | e13534 Background: Inhibitors of the mammalian target of rapamycin (mTOR) pathway including everolimus and temsirolimus are currently used for the treatment of several malignancies. Their applicati... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|